A Study of LY3532226 in Participants With Obesity

Launched by ELI LILLY AND COMPANY · Aug 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called LY3532226 to see if it is safe and how well it is tolerated by people with obesity. The main goal is to understand how the drug works in the body, including how much of it enters the bloodstream and how long it stays there. The study is divided into two parts: the first part will last about 16 weeks, and the second part will last around 20 weeks, not counting the time for screening participants.

To be eligible for this study, participants should be between 18 and 75 years old, weigh no more than 330 pounds, and have a body mass index (BMI) between 30 and 40, indicating obesity. Additionally, they should have stable body weight for at least three months before joining the trial. However, individuals with a history of serious mental health issues or certain medical conditions related to obesity may not qualify. Participants will undergo regular check-ups and blood tests during the study, and they will not be allowed to take other weight-loss medications while participating. This trial is currently recruiting participants, and anyone interested should discuss it with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body mass index (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²)
• • Have had a stable body weight that is less than or equal to 5% change in body weight for 3 months prior to screening and enrollment
• Exclusion Criteria:
• • Have a lifetime history of a suicide attempt
• • Have a history or presence of psychiatric disorders, including a history of major depressive disorder within the last 2 years
• • Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire
• • Have a known clinically significant gastric emptying abnormality, have undergone gastric bypass surgery or restrictive bariatric surgery
• • Have taken approved or investigational medication for weight loss, within the previous 3 months or 5 half-lives of study screening, whichever is earlier
• • Intend to use any weight-loss medications during study participation
• • Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity